PHGE trades 7209.1% below Wall Street's consensus target of $38.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PHGE achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, BiomX Inc. (PHGE) has a Wall Street consensus price target of $38.00, based on estimates from 5 covering analysts. With the stock currently trading at $0.45, this represents a potential upside of +7209.1%. The company has a market capitalization of $1.17B.
Analyst price targets range from a low of $38.00 to a high of $38.00, representing a 0% spread in expectations. The median target of $38.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PHGE trades at a trailing P/E of -0.0x. Analysts expect EPS to grow -31867.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
LSTALisata Therapeutics, Inc. | $32M | $3.47 | — | — | — | — | — |
ASMBAssembly Biosciences, Inc. | $400M | $25.15 | $45.00 | +84.1% | Buy | — | 11 |
ACXPAcurx Pharmaceuticals, Inc. | $2M | $1.51 | — | — | — | — | — |
PRAXPraxis Precision Medicines, Inc. | $8.8B | $303.00 | $584.00 | +106.9% | Buy | — | 16 |
CRSPCRISPR Therapeutics AG | $5.2B | $54.36 | $71.67 | +32.5% | Buy | — | 38 |
NTLAIntellia Therapeutics, Inc. | $1.8B | $15.75 | $26.13 | +66.8% | Buy | — | 39 |
EDITEditas Medicine, Inc. | $274M | $2.80 | $5.00 | +85.9% | Buy | — | 25 |
BEAMBeam Therapeutics Inc. | $3.7B | $35.53 | $48.00 | +40.6% | Buy | — | 27 |
PCVXVaxcyte, Inc. | $7.5B | $52.11 | $89.00 | +73.0% | Buy | — | 11 |
ILMNIllumina, Inc. | $24.5B | $161.38 | $151.40 | -6.5% | Buy | 31.0x | 50 |
Quick answers to the most common questions about buying PHGE stock.
The consensus Wall Street price target for PHGE is $38, representing 7209.1% upside from the current price of $0.45. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
PHGE has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $38 implies 7209.1% upside from current levels.
PHGE's current price is $0.45 with a consensus target of $38 (7209.1% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $38 for PHGE, while the most conservative target is $38. The consensus of $38 represents the median expectation. These targets typically reflect 12-month expectations.
PHGE is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PHGE stock forecast based on 5 Wall Street analysts shows a consensus price target of $38, with estimates ranging from $38 (bear case) to $38 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on PHGE, with a "Buy" consensus rating and $38 price target (7209.1% upside). 4 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PHGE analyst price targets range from $38 to $38, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $38 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.